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CLINICAL INVESTIGATION
Acute intradialytic well-being: Results of a clinical trial
comparing polysulfone with cuprophan
BERGAMO COLLABORATIVE DIALYSIS STUDY GROUP'
Acute intradialytic well-being: Results of a clinical trial comparing
polysulfone with cuprophan. We conducted a multicenter, randomized,
double-blin , controlled clinical trial to compare the effects of a
synthetic, hih-flux polysulfone membrane with a standard cuprophan
one on acm clinical complications during a diffusive dialysis proce-
dure. The principal end-point, that is, the number of hypotensive
episodes, was similar in polysulfone (39; 23.8%) and cuprophan (32;
19.5%). Likewise, no significant difference was found between the two
membranes as far as the secondary end-point was concerned, that is,
the effect on headache, nausea, pruritus and sense of well-being. We
conclud that high-flux polysulfone, acutely used in standard diffusive
dialysis, has no favorable influence on hypotensive episodes and does
not affect some typical dialysis-related symptoms any differently from
cuprophan membrane. The need is stressed for well-controlled studies
specifically designed to assess the worth of new dialysis techniques and
materials that may vastly raise the cost of dialysis treatment.
Hemodialysis has proved to be a remarkably safe procedure,
but several acute complications and symptoms associated with
it have been described. Intradialytic hypotension, muscle
cramps, headache, nausea, pruritus, fatigue and lack of energy
at the end of dialysis are the most frequent problems, and
numerous causal factors have been postulated [1—6]. In the last
few years biochemical and cellular phenomena induced by the
blood-membrane interaction have joined the list of possible
causes of dialysis-related problems [3, 6, 7—9].
A number of studies have investigated membrane-induced
complement activation [10—13], release of prostanoids [14—16],
interleukin 1 [17—21] oxygen free radicals [22, 23], and recently
2-microglobulin generation and clearance [24—26), comparing
the influence of different membranes on these phenomena.
These studies clearly showed that membranes made of syn-
thetic, non-cellulosic material such as polyacrylonitrile, poly-
methylmethacrylate and polysulfone, have a positive influence,
compared with cuprophan, on the biochemical and cellular
phenomena which arise from the blood-dialyzer interaction,
and as a consequence the use of these membranes has increased
vastly [27—30]. Despite this enthusiasm, and the ever growing
commercial success, only a limited number of trials, often with
n imprecise experimental design and small series of patients,
has attempted to clarify the clinical impact and relevance of
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these membranes on intradialytic symptoms. Yet the results of
these studies have been conflicting [9, 27, 31—41].
These considerations prompted us to design a multicenter,
controlled, randomized clinical trial to compare the effects of a
polysulfone filter and a standard cuprophan one [28, 41] on
acute complications and symptoms during a diffusive dialysis
procedure.
Methods
End-points
Reduction of intradialytic hypotension episodes with the use
of polysulfone membrane was the main end-point of the study.
A secondary end-point was to reduce the frequency of dialysis
induced headache, nausea, pruritus, and worsening of pre-
dialytic general well-being. These symptoms were assessed
before and immediately after the index dialysis using a subjec-
tive scoring system.
Study organization and eligibility criteria
Six dialysis units took part in the trial. All aspects of the
study protocol were approved by participating centers and
submitted to the patients for informed consent.
Patients on dialysis treatment for at least one month and
without acute illness were considered eligible. On the basis of
these criteria 428 out of 450 dialysis patients treated at the
participant centers were included.
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Dialysis procedure and monitoring
Every patient underwent the index dialysis at his center,
according to the usual dialysis schedule. The index dialysis was
a conventional diffusive treatment not differing from the proce-
dure usually employed for each patient with regard to duration
of the session, blood flow, dialysate flow and composition
(acetate 38 mEq/liter or bicarbonate 35 mEq/liter), with filter
and dialysis machine as the only variables introduced by the
study protocol.
We used 40 polysulfone or 8 js cuprophan hollow-fiber
filters, sterilized with ethylene oxide and with approximately 1
sq.m. surface area. The filters were fabricated by Bellco SpA,
Mirandola, Italy expressly for the study with nearly identical
small molecules dialysances, as assessed by urea and creatinine
clearances. Considering the different hydraulic permeability of
the two membranes we employed only dialysis monitors with
automatic volumetric control of ultrafiltration, without display
of transmembrane pressure. The weight decrease was kept
linear during the index dialysis. Water for dialysis was treated
by deionization.
Two to four nurses in each participating center were specially
trained for monitoring the patients, collecting and recording the
data required by the protocol.
Symptomatic hypotensive episodes were defined as blood
pressure fall of at least 25 mm Hg systolic and 10 mm Hg
diastolic accompanied by general discomfort, and requiring
some form of therapeutic intervention that was generally infu-
sion of variable amount of 0.9% saline depending on the
patient's clinical status. The subjective score for headache,
pruritus, nausea and general well-being was expressed by the
patients on a scale from 0 to 10 (0 = absence of symptoms; 10
= the highest level of a symptom; for well being 10 = total
well-being). Creatinine, BUN, Na and K were measured
before and after dialysis by standard techniques.
Randomization and double blindness
Double blind conditions were obtained with the use of the
dialyzers specially designed for the trial. The filters were
supplied with opaque housing making them identical in appear-
ance. A pre-trial test demonstrated that nurses and physicians
were unable to identify the type of membrane. Patients were
matched in pairs, according to body weight, within each center
and dialysis shift and then randomly allocated to one or the
other filter by tossing a coin. Each dialysis center received a
single large container with randomly numbered dialyzers and
the sequence of paired patients. The number of the filter
assigned to each patient was indicated on the clinical data
record forms.
Membrane markers
Complement activation and intradialytic changes of /32-micro-
globulin levels were determined as control markers of the two
filters in the first 20 consecutive pairs of dialysis procedures,
using the blood collected at the arterial and venous ends of the
circuit. Complement activation was assessed by measuring the
plasma concentration of C3a by radioimmunoassay (Human
Complement C3a desarg [1 125] assay system, Amersham,
U.K.] 0, 5, 15, 60 minutes from the start of dialysis. The plasma
concentration of 32-microglobulin was measured at the start
Table 1. Characteristics of patients
Cuprophan Polysulfone
Number 164 164
Males 102 93
Females 62 71
Age years
Mean 55.9 56.9
Range 19—80 17—79
Months on dialysis
Mean 74.9 81.1
Range 3—229 1—221
Number of diabetics 11 7
and end of dialysis by radioimmunoassay (p2 micro RIA 100,
Pharmacia Diagnostic, Uppsala, Sweden).
Statistical analysis
Hypotension differences between the two treatment groups
were followed by the closed sequential plan of Armitage [42], a
procedure based on pairing a patient randomly assigned to one
membrane with a patient randomly assigned to the other. With
an expected 25% incidence of hypotensive episodes, based on
the clinical records for the study population, the Armitage plan
was constructed with type I and II error rates at 5% and a
reduction of hypotensive episodes from 25% to 10% of dialysis
sessions. This plan required a maximum of 62 preferences and
a target sample size of 206 pairs.
Each index dialysis was simultaneously performed in a pair of
patients in the same dialysis room and with the same nurse, one
with the polysulfone and the other with the cuprophan mem-
brane, yielding a preference for either cuprophan or polysul-
fone. The hypotensive episodes during dialysis were on the
same day reported to the data collecting center, where the key
to randomization was kept and sequential plan produced. The
sequential plan was preferred to a cross-over design because of
the difficulties to have identical clinical, environmental and
nursing situations during two index dialysis in the same patient
(same hour of the day and day of the week, same water and
dialysate conditions, same nurse, same weight increase, etc.)
and consequent risks in the evaluation of the results [43]. With
the sequential plan we needed a larger number of patients to
compensate for not controlled, between-subjects variations.
Differences in the distribution of baseline characteristics,
dialysis parameters and subjective scores between the two
treatment groups were tested by the g test, Student's t-test, the
Mann-Whitney U test, two way analysis of variance with
Tukey's test, as appropriate. Data are expressed as mean SD
if not otherwise stated.
Results
Comparability of treatment groups and index dialysis
The distribution of selected baseline variables is shown in
Table 1. There were no significant differences between the two
groups. The distribution of different renal diseases was also
similar (data not shown). Forty-four patients in the cuprophan
group and 50 in the polysulfone group were receiving antihy-
pertensive drugs.
Selected variables during the index dialysis, shown in Table
2, were well comparable and not statistically different. In
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Iable 2. Characteristics of index dialysis
Cuprophan Polysulfone
Blood flow mI/mm 328 33 324 33
Dialysate flow mI/mm 500 500
Dialysate composition
Na mEqiliter 141.7 1.5 141.8 1.5
K mEq/liter 1.9 0.5 1.9 0.5
Patients on bicarbonate 28 20
Minutes of dialysis 243 22 239 19
Pre Post Pre Post
BUN mmol/liter 55.6 13.6 22.3 7.0 55.6 13.6 21.9 8.3
Creatinine p.mol/liter 972 221 486 141 954 186 468 124
Na mEqlliter 137.5 2.9 137.9 2.7 137.8 3.2 138.0 2.9
K mEqiliter 5.0 0.7 3.6 0.4 5.0 0.8 3.6 0.5
Weight kg 64.5 12 61.9 12 63.3 12 60.9 11
Systolic BP mm Hg 152 26 138 24 148 23 132 28
Diastolic BP mm Hg 85 14 81 14 84±13 79±16
Heart rate beats/mm 74 10 79 13 75 11 82 13
particular, the rate of weight decrease was similar (4.2% in
cuprophan group versus 3.9% in the polysulfone one) as well as
that of BUN and creatinine.
Hypotensive episodes
As shown in Figure 1, after evaluation of 164 pairs of patients
and 51 preferences the sequential-monitoring boundary at
which there was no significant difference between the two
groups of treatment was reached and the trial ended. Overall 71
hypotensive episodes were recorded, in 21.6% of dialysis
sessions, a slightly lower prevalence than expected. Thirty-two
episodes (19.5%) occurred in the cuprophan group and 39
(23.8%) in the polysulfone group. Each hypotensive episode
required 275 170 ml of saline in patients treated with
cuprophan and 266 115 ml in those with polysulfone. Hypo-
tension occurred on the average after 190 41 minutes of
dialysis in the cuprophan group and 167 52 minutes in the
polysulfone group.
Subjective scores
At the start of dialysis 12% of patients had a headache in the
polysulfone group and 7.3% in the cuprophan one, for pruritus
the percentages were 15.8% and 11% and for nausea 0.6% and
4%, respectively. For general well-being the mean pre-dialysis
score was 8 1.6 (range 3 to 10) in the polysulfone group and
8.3 1.6 (range 4 to 10) in the cuprophan group. It decreased to
6.9 2 (range 2 to 10) and to 7.4 1.9 (range 3 to 10),
respectively, at the end of dialysis. A pre-dialysis score of ten
(that is, total well-being) was expressed by 36 polysulfone
patients and 46 cuprophan patients, and after dialysis by 12
polysulfone and 26 cuprophan patients. Muscle cramps were
recorded in 11 patients in each group. Vomiting was recorded in
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Fig. 1. Sequential analysis of hypotensive
episodes. The abscissa represents the number of
preferences for cuprophan or polysulfone. The
ordinate shows the direction of preference (plot
moves up 1 unit if preference is for cuprophan and
down I unit if preference is for polysulfone). The
boundary at which there was no significant
difference was reached at the 51st preference with
7 excess preferences for cuprophan.
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Table 3. Symptoms scored pre- and post-index dialysis
Cuprophan Polysulfone
Pre Post Pre Post
Headache 0.17 0.6 0.55 1.4
(0—4) (0—10)
0.44 1.2 0.48 1.3
(0—6) (0—6)
Pruritus 0.44 1.4 0.61 1.6
(0—8) (0—8)
0.59 1.6 1.00 2.1
(0—10) (0—10)
Nausea 0.16 0.9 0.13 0.8
(0—8) (0—8)
0.01 0.1 0.07 0.4
(0—2) (0—4)
Well-being 8.27 1.6 7.43 1.9
(4—10) (3—10)
8.02 1.6 6.94 2.0
(3—10) (2—10)
Table 4. Symptoms scored after dialysis compared to the pre-dialysis
rating (no. of patients)
Cuprophan Polysulfone
Headache
Improved 6 13
Unchanged 133 134
Worse 25 17
Pruritus
Improved 9 15
Unchanged 135 124
Worse 20 25
Nausea
Improved 5 1
Unchanged 156 158
Worse 3 5
Well-being
Improved 18 19
Unchanged 63 44
Worse 83 101
six polysulfone patients and in three cuprophan patients, al-
ways concomitant with hypotensive episodes. No episode of
fever, chills, chest and back pain was recorded during the index
dialysis.
No difference was observed in the distribution of scores
between the two groups either pre- or post-dialysis (U test,
Table 3). Considering the pre- and post-dialysis changes as
decrease, increase or no change there was statistically no
difference between the two groups (Table 4). Only the differ-
ence in the well-being score approached significance in favor of
cuprophan (P = 0.076).
Membrane markers
The kinetics of C3a is shown in Figure 2. As expected during
dialysis with cuprophan membrane there was a significant
increase in plasma C3a, persisting up to 60 minutes in both the
arterial and venous sides of the circuit. In contrast, during
polysulfone membrane, dialysis plasma C3a rose significantly
only at 5 and 15 minutes in the venous side of the circuit. The
increase of plasma C3a was significantly greater during cu-
prophan than polysulfone dialysis. Figure 3 shows the pre- and
post-dialysis levels of plasma /32-microglobulin. With Cu-
prophan dialysis 2-microglobulin rose significantly while it
decreased significantly with polysulfone dialysis, as expected.
Discussion
Approximately one third of patients on maintenance hemo-
dialysis experience adverse symptoms such as hypotension,
muscle cramps, nausea, pruritus, headache, feeling of fatigue
and lack of energy during and after dialysis. These symptoms
are frequently assessed and used as end-points when dialysis
methods and materials are studied [1, 2]. They are thought to be
multifactorial in origin and possibly related to osmotic and
oncotic derangements of intravascular volume, to autonomic
neuropathy, effects of acetate and hypoxemia [3—51. The blood-
membrane interaction, the so-called membrane biocompatibil-
ity issue, has recently been added to this list of possible causes
but only few clinical trials have been exploring the problem, and
the published results show several discrepancies [27, 31—41, 44,
45].
In addition, the actual advantages of two other characteristics
of high flux, synthetic membranes, the high hydraulic perme-
ability and the capacity for clearing large molecules, that is,
/32-microglobulin, are other points still needing to be clarified
[46]. Moreover, the possible risks related to the transfer from
the dialysate to the blood of endotoxin or endotoxin fragments
Data are presented as means su (range) 0 5 10 15 20 25 30 35 40 45 50 55 60
3000
2000
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0
Time, minutes of dialysis
Fig. 2. First dialysis hour kinetic of plasma C3a in 20 pairs of patients.
Symbols are: () cuprophan artery; (I) cuprophan vein; (LI) polysul-
fone artery; (0) polysulfone vein. Data are presented as means 5EM.
*p < 0.01 versus time 0; #P < 0.001 versus polysulfone.
Fig. 3. Pre- and post-dialysis plasma levels of $2-microglobulin in 20
pairs of patients. Symbols are: (LI) cuprophan; () polysulfone. Data
are presented as means SEM. *P < 0.001 versus re-dialysis; °P <
0.001 versus polysulfone.
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through these membranes (the so-called backfiltration phenom-
enon) have recently been underlined [47—49].
Nevertheless, synthetic, high-flux membranes and many new
techniques that use these membranes are becoming increasingly
popular, at least in Europe [27, 29, 44].
Aiming to eliminate possible bias, our trial was randomized,
double blinded, with planned statistical power and closely
monitored. The two treatment groups were well matched for
entry criteria, dialysis procedure and variables. Even though
eight more patients on bicarbonate dialysis were randomized to
the cuprophane group, the difference was not statistically
significant (Table 2). The conventional diffusive technique was
used and no change was introduced in the routine dialytic
treatment of patients, apart from the membrane. As far as the
potential contribution of acetate to the adverse effects associ-
ated with the index dialysis, both filters had identical small
molecule dialysance (urea, creatinine) and had nearly identical
small surface area. Under these circumstances the influx of
acetate was likely to be comparable in both groups [50, 511.
Although the filters were specifically made for this study with
respect to surface area and opaque housing, the manufactoring
process did not differ from that usually employed and the
polysulfone was the same as that used in clinical practice [281.
The results of this cooperative trial clearly showed that there
was no significant improvement in the acute end-points studied
when a high-flux polysulfone membrane was used during rou-
tine diffusive dialysis.
As is often the case with some drugs, technological changes
or improvements do not necessarily translate into an improved
benefit to risk ratio. Formally controlled assessment of novel
technologies and procedures should be the rule at a very early
stage to avoid the risk of raising market and organizational
pressures with potentially important economic implications
[52]. We wish to note that if the "negative acute" results of this
double-blind study were applied to the health care system of a
country like Italy (with a population of 30,000 dialyzed patients
and where filter reuse is not permitted by law), the yearly
savings would be about $40 to 60 million US.
However, this study was designed to explore a limited
number of acute events. It cannot be excluded that the mem-
branes might display different biological effects under different
circumstances (large surface area filters, bicarbonate dialysis)
or during chronic treatment. Indeed, recent data show that
exposure to cuprophan but not to synthetic membranes causes
chronic adverse changes in the immune system [53] and an
accelerated protein catabolism [54].
The other important results of this double-blind randomized
trial lie in the subjective scores for well-being. It is clear that,
especially in a chronic condition such as dialytic treatment, the
subjective point of view should be allowed a decisive role. Its
evaluation should be pivotal, and it should be carefully mea-
sured on a pre/post-comparative basis to avoid attribution of
naturally and randomly occurring symptoms to the new or old
procedure.
Even though this trial did not aim to verify the role of dialysis
as an inducer of these symptoms, but to compare the two
membranes, our data do suggest that a score for general
well-being is a very sensitive way of investigating the acute
effects of a dialysis technique. A decrease from a pre-dialysis
score of about 8 to about 7 is indicative of passage from a state
of minor disability to a state of major disability [55]. By using
this score a large number of patients (more than 50%) with loss
of well-being after dialysis may be detected, regardless of the
membrane employed. Much less clear were the changes in the
incidence of other symptoms explored, with few patients show-
ing pre- and post-dialysis differences in either direction (im-
proved or worsened).
In summary a synthetic, high-flux membrane such as polysul-
fone, acutely used in standard diffusive dialysis, did not pro-
duce any improvement in the subjective index of the intradia-
lytic patient's well-being and did not reduce the incidence of
hypotensive episodes.
Well-controlled studies designed to assess the clinical impact
of new dialysis techniques and materials are essential.
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